Nath Bio-Genes (India) Ltd. (NATHBIOGEN) AI Stock Analysis

• Market Cap: ₹3.25B
• Dividend Yield: 1.19%
• Average Volume (3M): 2.58K
• Price to Earnings (P/E): 8.0
• Beta (1Y): 1.19
• Revenue Growth: 18.61%
• EPS Growth: 4.02%
• Country: IN
• Employees: 423
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Agricultural Inputs
• EPS (TTM): 18.53
• Shares Outstanding: 19,004,000
• 10 Day Avg. Volume: 2,256
• 30 Day Avg. Volume: 2,581
• PEG Ratio: -3.00
• Price to Book (P/B): 0.47
• Price to Sales (P/S): 0.82
• P/FCF Ratio: 31.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: ₹182.00 ▲(7.63% Upside)

Nath Bio-Genes' overall stock score is driven by its strong financial performance and attractive valuation. However, technical indicators suggest bearish momentum, which could pose short-term risks. The absence of earnings call and corporate event data limits the analysis to these factors.

Nath Bio-Genes (India) Ltd. Business Overview & Revenue Model

Company Description

Nath Bio-Genes (India) Ltd. (NATHBIOGEN) is a leading agricultural biotechnology company based in India, specializing in the development and production of hybrid seeds and agricultural inputs. The company operates primarily in the field of seed genetics and crop production, offering a diverse range of products including cotton, maize, and various vegetable seeds. NATHBIOGEN is committed to enhancing agricultural productivity through innovative research and development, focusing on sustainability and quality in agriculture.

How the Company Makes Money

Nath Bio-Genes generates revenue primarily through the sale of hybrid seeds and related agricultural products. Its revenue model is anchored in the development and commercialization of high-yield and pest-resistant seed varieties, which are sold to farmers across India and potentially in international markets. Key revenue streams include sales from hybrid seeds, as well as associated products such as fertilizers and crop protection chemicals which complement their seed offerings. The company also benefits from partnerships with agricultural research institutions and collaborations with other agribusiness companies, enhancing its R&D capabilities and expanding its market reach. Seasonal demand for seeds, driven by planting cycles and agricultural trends, significantly influences the company's earnings, alongside potential government policies supporting agricultural innovation.

Nath Bio-Genes (India) Ltd. Financial Statement Overview

Summary

Nath Bio-Genes has a strong profitability profile with healthy profit margins and revenue growth. The balance sheet shows financial stability with low debt and improved return on equity. However, there is variability in EBIT, EBITDA margins, and free cash flow, which could impact liquidity.

Income Statement

The company shows a solid performance in terms of profitability with a healthy gross profit margin and stable net profit margin. Revenue growth from 2024 to 2025 was significant, indicating a positive trajectory. However, EBIT and EBITDA margins have shown slight fluctuations over the years, suggesting some variability in operating efficiency.

Balance Sheet

Nath Bio-Genes maintains a strong equity base with a relatively low debt-to-equity ratio, indicating financial stability. The return on equity has improved, reflecting effective use of shareholder funds. However, the equity ratio indicates a moderate reliance on debt, which could pose risks if not managed carefully.

Cash Flow

The cash flow statement reflects a positive trend in free cash flow growth, indicating improved cash generation from operations. The operating cash flow to net income ratio suggests efficient conversion of income into cash. However, the free cash flow to net income ratio has shown variability, which may affect liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.05B	3.65B	2.48B	3.01B	2.78B	3.07B
Gross Profit	2.13B	2.29B	1.03B	1.67B	1.54B	1.71B
EBITDA	577.27M	497.98M	536.39M	488.91M	-497.06M	684.33M
Net Income	425.26M	386.00M	396.19M	350.11M	-673.38M	556.62M
Balance Sheet
Total Assets	0.00	10.26B	8.80B	7.93B	7.42B	7.90B
Cash, Cash Equivalents and Short-Term Investments	888.99M	888.99M	774.10M	379.90M	41.68M	292.11M
Total Debt	0.00	1.23B	1.10B	1.05B	929.59M	965.67M
Total Liabilities	-6.44B	3.82B	2.70B	2.20B	2.00B	1.76B
Stockholders Equity	6.44B	6.44B	6.10B	5.73B	5.42B	6.13B
Cash Flow
Free Cash Flow	0.00	96.61M	478.18M	358.18M	-39.70M	-104.86M
Operating Cash Flow	0.00	175.81M	745.94M	383.67M	170.46M	11.13M
Investing Cash Flow	0.00	-39.62M	-274.01M	-28.84M	-198.66M	-102.82M
Financing Cash Flow	0.00	-21.30M	-77.78M	-16.68M	-222.27M	164.01M

Nath Bio-Genes (India) Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 169.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATHBIOGEN, the sentiment is Positive. The current price of 169.1 is below the 20-day moving average (MA) of 170.69, below the 50-day MA of 171.35, and below the 200-day MA of 174.09, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 51.18 is Neutral, neither overbought nor oversold. The STOCH value of 27.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NATHBIOGEN.

Nath Bio-Genes (India) Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARIES	67 Neutral	₹5.16B	14.04	―	0.30%	19.25%	67.58%
NATHBIOGEN	65 Neutral	₹3.25B	8.02	―	1.19%	18.61%	4.02%
NOVAAGRI	64 Neutral	₹4.18B	15.42	―	―	―	―
HARRMALAYA	63 Neutral	₹3.64B	13.77	―	―	8.73%	―
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

Nath Bio-Genes (India) Ltd. Corporate Events

Nath Bio-Genes Ensures Regulatory Compliance with SEBI Regulations

Nath Bio-Genes (India) Ltd. has submitted a compliance certificate for the quarter ending September 30, 2025, in accordance with SEBI (Depositories and Participants) Regulations, 2018. This submission, confirmed by their Registrar and Share Transfer Agent, Bigshare Services Pvt. Ltd., ensures that all securities received for dematerialization have been processed and listed appropriately, maintaining regulatory compliance and transparency for stakeholders.